These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37334673)
41. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028 [TBL] [Abstract][Full Text] [Related]
45. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. Sghaier S; Corbaux P; Ray-Coquard I; Lim MC; Hasegawa K; Nieuwenhuysen EV; Gonzalez A; Raspagliesi F; Freyer G Future Oncol; 2023 Aug; 19(25):1715-1727. PubMed ID: 37650734 [TBL] [Abstract][Full Text] [Related]
46. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086 [TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR; N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847 [TBL] [Abstract][Full Text] [Related]
48. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677 [TBL] [Abstract][Full Text] [Related]
49. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517 [TBL] [Abstract][Full Text] [Related]